GLP-1RAs Linked to Reduced Disease Activity and Cardiovascular Risks in RA
The use of GLP-1RAs may improve RA disease activity and cardiovascular risk profiles among patients with overweight or obesity.
According to a study published in ACR Open Rheumatology, the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with improvements in rheumatoid arthritis (RA) disease activity and cardiovascular risk factors among patients with overweight or obesity.
Rheumatoid arthritis frequently coexists with obesity, which is linked to heightened inflammation, greater disease activity, and lower response to therapy.
Researchers conducted a single-center, retrospective observational study at the University of California, Los Angeles, that included patients with RA and a body mass index (BMI) of at least 27 kg/m2.
Author's summary: GLP-1RAs reduce disease activity.